Welcome to LookChem.com Sign In|Join Free

Product Name

  • or
Home > Products > 

Sodium 2-propylpentanoate

  • Name Sodium 2-propylpentanoate
  • EINECS213-961-8
  • CAS No. 1069-66-5
  • Density1.0803 g/cm3
  • PSA40.13000
  • LogP0.95270
  • Solubilitywater: 50 mg/mL
  • Melting Point300 °C
  • FormulaC8H15NaO2
  • Boiling Point220 °C at 760 mmHg
  • Molecular Weight166.196
  • Flash Point116.6 °C
  • Transport InformationN/A
  • AppearanceWhite solid
  • Safety36/37-53-45-37/39-26-36
  • Risk Codes22-61-36/38-36/37/38
  • Molecular Structure
    Molecular Structure of 1069-66-5 (Sodium 2-propylpentanoate)
  • Hazard SymbolsHarmfulXn,ToxicT,IrritantXi
  • SynonymsHarmfulXn,ToxicT,IrritantXi
  • Article Data8

Sodium 2-propylpentanoate Synthetic route

99-66-1

valproic acid

1069-66-5

sodium valproate

Conditions
ConditionsYield
With sodium hydroxide In water Product distribution / selectivity;100%
With sodium hydroxide In water at 20℃;100%
With sodium hydroxide In toluene97.7%
With sodium hydroxide
17022-31-0

ethyl 2-propylpentanoate

1069-66-5

sodium valproate

Conditions
ConditionsYield
With methanol; sodium hydroxide for 9h; Time; Reflux; Large scale;87.2%
106-94-5

propyl bromide

105-53-3

diethyl malonate

1069-66-5

sodium valproate

Conditions
ConditionsYield
Stage #1: propyl bromide; diethyl malonate With sodium ethanolate In ethanol at 50℃; for 2h;
Stage #2: With sodium hydroxide In water at 60℃; for 3h;
Stage #3: at 110℃;

copper(II) choride dihydrate

1069-66-5

sodium valproate

108558-25-4

Cu2(valproate)4

Conditions
ConditionsYield
In water for 24h;99%
52462-29-0

[ruthenium(II)(η6-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]2

1069-66-5

sodium valproate

[RuCl(κ2O-vpCO2)(η6-p-cymene)]

Conditions
ConditionsYield
In methanol at 20℃; for 2h;96%
99-66-1

valproic acid

1069-66-5

sodium valproate

divalproex sodium

Conditions
ConditionsYield
In acetonitrile Product distribution / selectivity; Heating / reflux;93.75%
In acetone at 50℃; for 0.166667h;

1,1'-(2,2'-dimethoxy-[1,1'-binaphthalene]-6,6'-diyl)bis(2-bromoethanone)

1069-66-5

sodium valproate

(2,2'-dimethoxy-[1,1'-binaphthalene]-6,6'-diyl)bis(2-oxoethane-2,1-diyl) bis(2-propylpentanoate)

Conditions
ConditionsYield
In acetonitrile at 20℃; for 4h;92%
1069-66-5

sodium valproate

7646-85-7

zinc(II) chloride

zinc(II) valproate

Conditions
ConditionsYield
In water88%
1069-66-5

sodium valproate

7646-85-7

zinc(II) chloride

[Zn2(valproate)4]

Conditions
ConditionsYield
In water at 20℃;88%
1069-66-5

sodium valproate

7646-85-7

zinc(II) chloride

[tetrakis-μ-2-propylpentanoatezinc(II)]

Conditions
ConditionsYield
In water at 20℃; for 24h;88%
In water at 20℃; for 1h;

Sodium 2-propylpentanoate Specification

The IUPAC name of Sodium valproate is sodium 2-propylpentanoate. With the CAS registry number 1069-66-5, it is also named as 2-Propylpentanoic acid sodium salt. The product's categories are Valproic acid Series; Intermediates & Fine Chemicals; Pharmaceuticals; GABA/Glycine Receptor. Besides, it is white solid, which should be stored in sealed container in cool and dry place. In addition, its molecular formula is C8H15NaO2 and molecular weight is 166.19.

The other characteristics of Sodium valproate can be summarized as: (1)EINECS: 213-961-8; (2)ACD/LogP: 2.72; (3)# of Rule of 5 Violations: 0; (4)ACD/LogD (pH 5.5): 1.95; (5)ACD/LogD (pH 7.4): 0.16; (6)ACD/BCF (pH 5.5): 11.78; (7)ACD/BCF (pH 7.4): 1; (8)ACD/KOC (pH 5.5): 123.33; (9)ACD/KOC (pH 7.4): 2; (10)H bond acceptors: 2; (11)H bond donors: 1; (12)Freely Rotating Bonds: 5; (13)Polar Surface Area: 37.3 Å2; (14)Density: g/cm3; (15)Flash Point: 116.6 °C; (16)Melting point: 300 °C; (17)Solubility: H2O: 50 mg/mL; (18)Enthalpy of Vaporization: 50.29 kJ/mol; (19)Boiling Point: 220 °C at 760 mmHg; (20)Vapour Pressure: 0.0435 mmHg at 25 °C.

Preparation and Uses of Sodium valproate: it can be produced by Diethyl malonate. Furthermore, this chemical is an anticonvulsant which can be used in the treatment of epilepsy and bipolar disorder.

When you are using this chemical, please be cautious about it as the following: it is harmful if swallowed. And it is also irritating to eyes, respiratory system and skin. You should wear suitable protective clothing, gloves and eye / face protection. Moreover, this product may cause harm to the unborn child. Please avoid exposure - obtain special instructions before use. And in case of contact with eyes, please rinse immediately with plenty of water and seek medical advice. Additionally, in case of accident or if you feel unwell, please seek medical advice immediately (show the label whenever possible.) 

People can use the following data to convert to the molecule structure.
(1)SMILES:[Na+].[O-]C(=O)C(CCC)CCC
(2)InChI:InChI=1/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1
(3)InChIKey:AEQFSUDEHCCHBT-REWHXWOFAT
(4)Std. InChI:InChI=1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1
(5)Std. InChIKey:AEQFSUDEHCCHBT-UHFFFAOYSA-M

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LD50 intraperitoneal 565mg/kg (565mg/kg)   Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 13, Pg. 81, 1977.
child LDLo oral 750mg/kg (750mg/kg) BEHAVIORAL: COMA

CARDIAC: OTHER CHANGES

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Lancet. Vol. 1, Pg. 221, 1984.
child TDLo oral 1820mg/kg/12W (1820mg/kg) BEHAVIORAL: SLEEP

GASTROINTESTINAL: NAUSEA OR VOMITING
Lancet. Vol. 2, Pg. 1110, 1980.
dog LD50 intraperitoneal 700mg/kg (700mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA

BEHAVIORAL: TREMOR
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
dog LD50 oral 1420mg/kg (1420mg/kg) BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA

GASTROINTESTINAL: NAUSEA OR VOMITING
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
guinea pig LD50 oral 824mg/kg (824mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
hamster LD50 oral 1740mg/kg (1740mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
infant LDLo oral 250mg/kg/10D- (250mg/kg) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF ENDOCRINE PANCREAS

BLOOD: HEMORRHAGE
Archives of Disease in Childhood. Vol. 58, Pg. 543, 1983.
man TDLo oral 17mg/kg (17mg/kg) BRAIN AND COVERINGS: OTHER DEGENERATIVE CHANGES

LIVER: LIVER FUNCTION TESTS IMPAIRED

BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)
Journal of Toxicology, Clinical Toxicology. Vol. 30, Pg. 209, 1992.
man TDLo oral 214mg/kg/30D- (214mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" Israel Journal of Medical Sciences. Vol. 30, Pg. 283, 1994.
mouse LD50 intramuscular 832mg/kg (832mg/kg)   Biochemical Pharmacology. Vol. 22, Pg. 1701, 1973.
mouse LD50 intraperitoneal 470mg/kg (470mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
mouse LD50 intravenous 750mg/kg (750mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA
Arzneimittel-Forschung. Drug Research. Vol. 26, Pg. 299, 1976.
mouse LD50 oral 977mg/kg (977mg/kg)   European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 25, Pg. 71, 1990.
mouse LD50 subcutaneous 860mg/kg (860mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA

BEHAVIORAL: TREMOR
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
mouse LD50 unreported 1700mg/kg (1700mg/kg)   United States Patent Document. Vol. #3301754,
rabbit LD50 intraperitoneal 1200mg/kg (1200mg/kg)   Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 13, Pg. 81, 1977.
rabbit LD50 oral 1468mg/kg (1468mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 5, Pg. 41, 1971.
rat LD50 intraperitoneal 970mg/kg (970mg/kg) BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
rat LD50 intravenous 509mg/kg (509mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 1155, 1983.
rat LD50 oral 670mg/kg (670mg/kg)   British Journal of Pharmacology. Vol. 74, Pg. 957P, 1981.
rat LD50 subcutaneous 1029mg/kg (1029mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 5, Pg. 41, 1971.
women TDLo oral 500mg/kg (500mg/kg) BEHAVIORAL: SLEEP

BEHAVIORAL: MUSCLE WEAKNESS
Postgraduate Medical Journal. Vol. 62, Pg. 409, 1986.
women TDLo oral 1040mg/kg (1040mg/kg) BRAIN AND COVERINGS: CHANGES IN SURFACE EEG

BEHAVIORAL: COMA

BLOOD: THROMBOCYTOPENIA
Journal of Toxicology, Clinical Toxicology. Vol. 33, Pg. 279, 1995.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1069-66-5
Related Products

Hot Products

Post a RFQ